Analysts Set Average Target Price of $53.00 for Omnicell,
November 29, 2023
🌥️Trending News
Analysts have recently set a $53.00 average target price for Omnicell ($NASDAQ:OMCL), Inc., a technology and products provider for medication and supply management solutions to healthcare organizations worldwide. Omnicell, Inc. is a publicly-traded company on the NASDAQ Global Select Market (OMCL). The company designs, manufactures, and supplies automation and business analytics software for medication and supply management to healthcare systems, pharmacies, long-term care, assisted living, behavioral health and post-acute care facilities. Their products are designed to help healthcare facilities improve operational efficiency, reduce risk of medication errors, improve patient safety, and provide better medication access to patients.
Their product line includes automated drug storage systems, automated dispensing cabinets, central pharmacy automation systems, barcode label printing systems, software solutions, and other ancillary products. In addition to providing products for medication and supply management, the company also provides professional services such as product implementation, installation, and training. This presents an opportunity for investors to capitalize on the growth of this leading provider of medication and supply management solutions.
Stock Price
This increase in stock value is noteworthy in light of the current volatile market conditions. While the future of the stock is yet to be seen, analysts remain confident in their target price assessment, and it is likely that further movement in the stock’s value will be observed in coming weeks and months. Omnicell“>Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Omnicell. More…
| Total Revenues | Net Income | Net Margin |
| 1.19k | -34.4 | -2.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Omnicell. More…
| Operations | Investing | Financing |
| 224.83 | -59.9 | 13.85 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Omnicell. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.22k | 1.03k | 25.74 |
Key Ratios Snapshot
Some of the financial key ratios for Omnicell are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 10.0% | 26.3% | -4.2% |
| FCF Margin | ROE | ROA |
| 13.9% | -2.7% | -1.4% |
Analysis
We at GoodWhale have examined the fundamentals of OMNICELL and our Star Chart shows that OMNICELL is strong in growth, medium in asset, profitability and weak in dividend. We classify OMNICELL as an ‘elephant’, meaning that it is a company with significant assets available after deducting off liabilities. Such companies may be of interest to investors who are seeking stability and long-term investments, such as institutional investors. Furthermore, OMNICELL has a high health score of 8/10 with regards to its cashflows and debt. This means that it is capable of paying off debt and funs future operations without difficulty. More…
Peers
The company’s products are used by hospitals, nursing homes, home health agencies, and other healthcare providers. Omnicell Inc’s competitors include Nexus AG, PrimeCare Systems Inc, 10x Genomics Inc, and other companies that provide similar products and services.
– Nexus AG ($LTS:0FGL)
Nexus AG is a German software company that specializes in enterprise resource planning (ERP) software. The company has a market capitalization of 814.29 million euros as of 2022 and a return on equity of 11.21%. Nexus AG’s main competitors include SAP SE, Oracle Corporation, and Microsoft Corporation.
– PrimeCare Systems Inc ($OTCPK:PCYS)
PrimaCare Systems Inc is a publicly traded company with a market capitalization of $44.19 million as of March 2022. The company has a return on equity of 9.24%. PrimaCare Systems Inc is a healthcare technology company that provides software and services to healthcare providers.
– 10x Genomics Inc ($NASDAQ:TXG)
10x Genomics Inc is a life sciences company that develops and sells products and services for genomic analysis. The company’s products include sequencing services, software, and tools for analyzing genomic data. 10x Genomics was founded in 2012 and is headquartered in Pleasanton, California.
10x Genomics has a market cap of $3.07 billion as of 2022 and a return on equity of -10.81%. The company’s products are used for genomic sequencing and analysis, and its services include software and tools for analyzing genomic data. 10x Genomics was founded in 2012 and is headquartered in Pleasanton, California.
Summary
Investment analysts have given Omnicell, Inc. an average target price of $53.00. This means that analysts expect the stock to hit this price point in the future. The target price takes into account a company’s fundamentals, competitive landscape, industry trends, and other external factors that may affect its stock price.
Analysts may also assess the potential upside or downside of the stock, and adjust the target price accordingly. Investors should research the company and review the target price when considering investing in Omnicell, Inc.
